For a Limited Time Only!
BGI has been providing world-class metagenomic sequencing services for more than 10 years. We have processed over 96,000 samples from partners across the world on our own DNBSEQTM technology platforms and have published more than 70 papers in the world's leading journals.
For a limited time, we are offering a spring discount for our metagenomic sequencing services, including both library construction and sequencing:
Key Terms and Conditions:
- This promotion cannot be accumulated with any other offer.
- The promotion terms are only eligible for contracts signed before June 30th, 2022.
- This promotion includes library construction and sequencing.
- Sequencing performed on DNBSEQTM, PE150.
-This promotion is for metagenomic sequencing 5Gb and 10Gb packages only.
- Additional terms may apply, contact us for details.
Intact genomic DNA ≥1 μg
Concentration ≥12.5 ng/μL
Volume ≥15 μL
300-400bp short insert library
PE150
Guaranteed ≥80% of bases with quality score of ≥Q30
Typical 30 working days delivery from sample QC acceptance to filtered clean data availability
Data available in standard FASTQ file formats
Custom bioinformatics analysis options available
BGI metagenomic sequencing services are typically executed with our proprietary DNBSEQ™ NGS technology platform, for great sequencing data at the lowest cost in the industry.
DNBSEQ™ is a proprietary sequencing technology, first developed by BGI's Complete Genomics subsidiary in Silicon Valley, and can offer advantages in terms of lower amplification error rates and much lower duplication rates for some sequencing applications. In addition, studies have shown the index hopping rate in DNBSEQ™ platforms can be much lower when compared to that of other platforms.
CopyrightⒸ BGI 2024. All rights reserved. All product names, logos, and brands are property of their respective owners. All company, product and service names used in this email are for identification purposes only. Use of these names, logos, and brands does not imply endorsement. This email contains information on services or products targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information, which may not comply with any legal process, regulation, registration, or usage in the country of your origin. We hereby disclose that this email communication is for commercial purposes. Unless otherwise informed, certain sequencers and sequencing reagents are not available in selected countries or regions. Please get in touch with a representative for regional availability. The company reserves the right of final interpretation.